Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are a major
cause of acute respiratory failure in the critically ill patient. ALI and ARDS are characterized …

Background In a previous randomised controlled phase 2 trial, intravenous infusion of
salbutamol for up to 7 days in patients with acute respiratory distress syndrome (ARDS) …

Abstract Coronavirus disease 2019 (COVID-19) is highly infectious. It has been highlighted
that if not expertly and individually managed with consideration of the vasocentric features, a …

Rationale: Experimental data suggest that manipulation of alveolar fluid clearance with β-
agonists can accelerate the resolution of alveolar edema and improve survival. Objective: To …

These studies were undertaken to extend emerging evidence that β 2 adrenergic receptor (β
2 AR) agonists, in addition to their bronchorelaxing effects, may have broad anti …

Rationale: Experimental studies suggest that pretreatment with β-agonists might prevent
acute lung injury (ALI). Objectives: To determine if in adult patients undergoing elective …

Background: Acute lung injury is an important cause of respiratory failure in the critically ill
patient. It is caused by damage to the alveolar barrier with subsequent alveolar flooding …

As a syndrome of injurious pulmonary inflammation resulting in deranged respiratory
physiology, acute lung injury affords numerous potential therapeutic targets. Two main …

Ricin, a plant-derived toxin originating from the seeds of Ricinus communis (castor beans),
is one of the most lethal toxins known, particularly if inhaled. Ricin is considered a potential …

Inhaled long-acting β-adrenergic agonists (LABAs) and short-acting β-adrenergic agonists
are approved for the treatment of obstructive lung disease via actions mediated by β 2 …